| P | pCR | non-pCR | P | ||
| n | Percentage | n | Percentage | ||
| Age (years) |
|
|
|
|
|
| ≥50 | 5 | 9.8 | 20 | 39.1 | 0.187 |
| <50 | 4 | 7.8 | 22 | 43.1 | |
| Menopausa |
|
|
|
|
|
| No | 3 | 5.9 | 19 | 37.3 | 0.420 |
| Yes | 6 | 11.8 | 23 | 45.1 | |
| Paracentesis type |
|
|
|
|
|
| Invasiveduct carcinoma | 8 | 15.8 | 30 | 58.8 | 0.736 |
| Invasive small-leaf cancer | 0 | 0 | 2 | 3.9 | |
| Myeloid cancer | 1 | 1.9 | 0 | 0 | |
| TNM periodization |
|
|
|
|
|
| IIb | 2 | 3.9 | 12 | 23.5 | 0.834 |
| IIIa | 7 | 13.7 | 25 | 49 | |
| IIIb | 0 | 0 | 3 | 5.9 | |
| IIIc | 0 | 0 | 1 | 1.9 | |
| ER |
|
|
|
|
|
| Negative | 6 | 11.8 | 10 | 19.6 | 0.920 |
| Positive | 3 | 5.9 | 31 | 60.8 | |
| PR |
|
|
|
|
|
| Negative | 7 | 13.7 | 13 | 25.5 | 0.818 |
| Positive | 2 | 3.9 | 29 | 56.9 | |
| Her-2 |
|
|
|
|
|
| Negative | 8 | 15.7 | 33 | 64.7 | 0.501 |
| Positive | 1 | 2 | 9 | 17.6 | |
| Chemotherapy programme |
|
|
|
|
|
| TEC | 9 | 17.6 | 32 | 62.2 | 0.666 |
| EC-T | 0 | 0 | 4 | 7.8 | |
| FEC-T | 0 | 0 | 4 | 7.8 | |
| NP | 0 | 0 | 2 | 3.9 | |
| Preoperative chemotherap |
|
|
|
|
|
| ≤3 | 4 | 5.9 | 19 | 54.9 | 0.002 |
| >3 | 5 | 11.8 | 23 | 27.5 | |
| Molecular typing |
|
|
|
|
|
| Luminal subtype | 2 | 3.9 | 32 | 62.2 | 0.007 |
| Her2 over-expression | 4 | 7.8 | 5 | 9.8 | |
| Triple Negative subtype | 5 | 5.8 | 5 | 9.8 | |